ASAnja Sander

Anja Sander

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anja Sander has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Preoperative Injection of Botulinum Toxin Into the Sphincter of Oddi Does Not Prevent Pancreatic Fistula After Distal Pancreatectomy: The Randomized Controlled PREBOTPilot Trial

    by Claudia E. Mack, Rosa Klotz, Ulla Klaiber, Peter Sauer, Anja Sander, Lukas Baumann, Friederike Schäfer, Alexandra Kunz, Markus W. Büchler, Thilo Hackert

    Objective: To investigate whether preoperative injection of botulinum toxin (BTX) into the sphincter of Oddi (SO) is a safe and feasible strategy to prevent postoperative pancreatic fistula (POPF) after distal pancreatectomy (DP). Summary Background Data: POPF remains a common and potentially serious complication following DP, affecting up to 30% of patients. Pharmacologically induced sphincter relaxation by endoscopic injection of BTX into the SO has been described as a new approach to prevent POPF after DP by improved drainage of pancreatic fluid towards the duodenum. Methods: Patients scheduled for elective primary distal pancreatectomy (DP), irrespective of the underlying disease, were included in this monocenter, randomized controlled, open-label, phase-II trial with 2 parallel arms. Patients randomly assigned to the intervention group received an endoscopic injection of BTX (100 units) into the SO 3–10 days before surgery. Patients in the control group did not undergo any preoperative intervention. The combined primary endpoint was defined as the occurrence of clinically relevant postoperative pancreatic fistula (POPF grades B/C) and/or death due to any cause within 30 days following DP. Results: From March 2020 to August 2023, 50 patients were included in the trial. Subsequent to the analysis of the primary endpoint, which revealed no tendency of a beneficial effect on the rate of POPF after DP following BTX injection, even with the most favorable outcome upon further inclusion of the remaining 10 patients planned for recruitment, the recruitment was prematurely terminated. All 26 patients in the intervention group underwent successful SO BTX injection within a median of 6 (IQR of 5–8) days before surgery. DP was performed in 41 patients (82%). Postinterventional pancreatitis was not detected. Within 30 days, POPF grade B/C occurred in 6 patients in the intervention and 3 patients in the control group (28.6% vs. 15%, P =0.294). One patient in the intervention group died during the trial due to POPF-induced postpancreatectomy hemorrhage (PPH). Conclusion: Preoperative injection of BTX into the SO did not reduce clinically relevant POPF or 30-day mortality following DP, and the trial was prematurely terminated for futility. Although the intervention was safe and feasible, these findings do not support its use for the prevention of POPF after DP.

  • Open Access

    Laparoscopic Resection Rectopexy Versus Delorme’s Procedure In Full-thickness Rectal Prolapse

    by Florian Herrle, Flavius Sandra-Petrescu, Simone Rothenhoefer, Julia Hardt, Steffen Seyfried, Andreas Joos, Alexander Herold, Dieter Bussen, Stefan Post, Marion Brunner, et al.

    Objective: The DELORES trial investigated whether laparoscopic resection rectopexy (LRR) is superior to Delorme’s procedure (DP) in full-thickness rectal prolapse. Background: Multiple perineal and transabdominal procedures are current practice for rectal prolapse surgery. Evidence from adequately designed randomized studies addressing the question of which of these procedures are superior in terms of recurrence and bowel function is lacking. Methods: DELORES was a randomized, observer-blinded, expertise-based multicenter trial. Patients with full-thickness rectal prolapse were eligible. The primary outcome was time to recurrence of full-thickness rectal prolapse within 24 months after primary surgery. The main secondary endpoints were morbidity, hospital stay, quality of life, constipation, and fecal incontinence (DRKS00000482). Results: A total of 358 patients were screened between September 2010 and January 2016. Based on screening, 70 patients were randomized and 65 were included in the analysis (33 LRR and 32 DP procedures). The median follow-up was 23.9 months. Analysis of the primary outcome showed that LRR was superior to DP ( P =0.0012). During the 24-month follow-up, 8.2% of patients in the LRR group had a full-thickness prolapse recurrence versus 42.8% in the DP group. The median time to recurrence was 17.8 months for LRR and 8.2 months for DP. The median duration of surgery was 212 min (LRR) versus 77 min (DP). Overall postoperative morbidity was low. The reoperation rate was higher for DP (0% LRR vs. 33.3% DP). Quality of life (FIQL) and incontinence scores (Wexner) were more favorable for LRR at 24-month follow-up. Conclusions: LRR is superior to DP in terms of recurrence and has favorable functional results.


  • Open Access

    Daily AI-Based Treatment Adaptation under Weekly Offline MR Guidance in Chemoradiotherapy for Cervical Cancer 1: The AIM-C1 Trial

    by Fabian Weykamp, Eva Meixner, Nathalie Arians, Philipp Hoegen-Saßmannshausen, Ji-Young Kim, Bouchra Tawk, Maximilian Knoll, Peter Huber, Laila König, Anja Sander, et al.

    (1) Background: External beam radiotherapy (EBRT) and concurrent chemotherapy, followed by brachytherapy (BT), offer a standard of care for patients with locally advanced cervical carcinoma. Conventionally, large safety margins are required to compensate for organ movement, potentially increasing toxicity. Lately, daily high-quality cone beam CT (CBCT)-guided adaptive radiotherapy, aided by artificial intelligence (AI), became clinically available. Thus, online treatment plans can be adapted to the current position of the tumor and the adjacent organs at risk (OAR), while the patient is lying on the treatment couch. We sought to evaluate the potential of this new technology, including a weekly shuttle-based 3T-MRI scan in various treatment positions for tumor evaluation and for decreasing treatment-related side effects. (2) Methods: This is a prospective one-armed phase-II trial consisting of 40 patients with cervical carcinoma (FIGO IB-IIIC1) with an age ≥ 18 years and a Karnofsky performance score ≥ 70%. EBRT (45–50.4 Gy in 25–28 fractions with 55.0–58.8 Gy simultaneous integrated boosts to lymph node metastases) will be accompanied by weekly shuttle-based MRIs. Concurrent platinum-based chemotherapy will be given, followed by 28 Gy of BT (four fractions). The primary endpoint will be the occurrence of overall early bowel and bladder toxicity CTCAE grade 2 or higher (CTCAE v5.0). Secondary outcomes include clinical feasibility, quality of life, and imaging-based response assessment.


  • Open Access

    Phase I trial of donor-derived modified immune cell infusion in kidney transplantation

    by Christian Morath, Anita Schmitt, Christian Kleist, Volker Daniel, Gerhard Opelz, Caner Süsal, Eman Ibrahim, Florian Kälble, Claudius Speer, Christian Nusshag, et al.

    BACKGROUND. Preclinical experiments have shown that donor blood cells, modified in vitro by an alkylating agent (modified immune cells [MICs]), induced long-term specific immunosuppression against the allogeneic donor. METHODS. In this phase I trial, patients received either 1.5 × 106 MICs per kg BW on day –2 (n = 3, group A), or 1.5 × 108 MICs per kg BW on day –2 (n = 3, group B) or day –7 (n = 4, group C) before living donor kidney transplantation in addition to post-transplantation immunosuppression. The primary outcome measure was the frequency of adverse events (AEs) until day 30 (study phase) with follow-up out to day 360. RESULTS. MIC infusions were extremely well tolerated. During the study phase, 10 treated patients experienced a total of 69 AEs that were unlikely to be related or not related to MIC infusion. No donor-specific human leukocyte antigen Abs or rejection episodes were noted, even though the patients received up to 1.3 × 1010 donor mononuclear cells before transplantation. Group C patients with low immunosuppression during follow-up showed no in vitro reactivity against stimulatory donor blood cells on day 360, whereas reactivity against third-party cells was still preserved. Frequencies of CD19+CD24hiCD38hi transitional B lymphocytes (Bregs) increased from a median of 6% before MIC infusion to 20% on day 180, which was 19- and 68-fold higher, respectively, than in 2 independent cohorts of transplanted controls. The majority of Bregs produced the immunosuppressive cytokine IL-10. MIC-treated patients showed the Immune Tolerance Network operational tolerance signature. CONCLUSION. MIC administration was safe and could be a future tool for the targeted induction of tolerogenic Bregs. TRIAL REGISTRATION. EudraCT number: 2014-002086-30; ClinicalTrials.gov identifier: NCT02560220. FUNDING. Federal Ministry for Economic Affairs and Technology, Berlin, Germany, and TolerogenixX GmbH, Heidelberg, Germany.


  • Open Access

    Prostate bed irradiation with alternative radio-oncological approaches (PAROS) - a prospective, multicenter and randomized phase III trial

    by Stefan A. Koerber, Sonja Katayama, Anja Sander, Cornelia Jaekel, Matthias F. Haefner, Juergen Debus, Klaus Herfarth

    For patients with treatment-naïve carcinoma of the prostate, hypofractionated irradiation becomes more and more popular. Due to the low α/β value of prostate cancer, increased single dose leading to a shortened treatment period seems to be safe and feasible. However, reliable data is lacking for post-prostatectomy patients so far. Further, the role of proton therapy is still under debate. Two prospective phase II trials with both, hypofractionated photon and proton therapy, provided promising results. The PAROS trial is a prospective, multicenter and randomized phase III trial for men with localized prostate carcinoma after surgery. Post-prostatectomy patients will be randomized to either normofractionated radiotherapy (nRT) with photons (70.0/ 2.0 Gy), or hypofractionated radiotherapy (hRT) with photons (57.0/ 3.0 Gy) or hRT with protons (57.0/ 3.0 Gy relative biological effectiveness [RBE]). Block randomization is stratified by Gleason Score (≤ 7 vs. > 7) and treatment indication (adjuvant vs. salvage). The trial is planned to enroll 897 patients. The primary objective is to show an improvement in the bowel-score according to EORTC QLQ-PR25 after proton therapy compared to photon irradiation (week 12 vs. baseline). Secondary aims are non-inferiority of hRT compared to nRT with regard to biochemical progression-free survival (bPFS), overall survival (OS), quality of life and toxicity. The present study aims to evaluate the role of hypofractionated radiotherapy to the prostate bed with photons and protons leading to significant impact on future management of operated men with prostate cancer. Deutsches Register klinischer Studien: DRKS00015231 ; registered 27 September 2018.


  • Are we preparing future doctors to deal with emotionally challenging situations? Analysis of a medical curriculum

    by Franziska Baessler, Ali Zafar, Sophie Schweizer, Anja Ciprianidis, Anja Sander, Stella Preussler, Hannah Honecker, Michael Wolf, Marina Bartolovic, Fabienne Louise Wagner, et al.


  • Blinded sample size recalculation in clinical trials with binary composite endpoints

    by Anja Sander, Geraldine Rauch, Meinhard Kieser

    We consider clinical trials with a binary composite endpoint where the trial is successful when a significant result is achieved for the composite or one prespecified main component. Appropriate sample size planning is challenging in this situation, as in addition to the Type I error rate, power, and target difference the overall event rates and the correlation between the test statistics have to be defined. Reliable estimates of these quantities, however, are usually hard to obtain and therefore there is a high risk to not achieve the intended power in a fixed sample size design. In this article, we propose an internal pilot study design where the nuisance parameters are estimated in a blinded way at an interim stage and where the sample size is then revised accordingly. We investigate the characteristics of the proposed design with respect to the actual Type I error rate, power, and sample size. The application of this design is illustrated by a clinical trial example.


  • Open Access

    Comparing systemic therapy and cognitive behavioral therapy for social anxiety disorders: study protocol for a randomized controlled pilot trial

    by Christina Hunger, Rebecca Hilzinger, Theresa Koch, Johannes Mander, Anja Sander, Hinrich Bents, Jochen Schweitzer

    Social anxiety disorders are among the most prevalent anxiety disorders in the general population. The efficacy of cognitive behavioral therapy (CBT) for social anxiety disorders is well demonstrated. However, only three studies point to the efficacy of systemic therapy (ST) in anxiety disorders, and only two of them especially focus on social anxiety disorders. These ST studies either do not use a good comparator but minimal supportive therapy, they do not use a multi-person ST but a combined therapy, or they do not especially focus on social anxiety disorders but mood and anxiety disorders in general. Though ST was approved as evidence based in Germany for a variety of disorders in 2008, evidence did not include anxiety disorders. This is the first pilot study that will investigate multi-person ST, integrating a broad range of systemic methods, specifically for social anxiety disorders and that will compare ST to the "gold standard" CBT. This article describes the rationale and protocol of a prospective, open, interventive, balanced, bi-centric, pilot randomized controlled trial (RCT). A total of 32 patients with a primary SCID diagnosis of social anxiety disorder will be randomized to either CBT or ST. Both treatments will be manualized. The primary outcome will include social anxiety symptoms at the end of therapy. Therapy will be restricted to no more than 26 hours (primary endpoint). Secondary outcomes will include psychological, social systems and interpersonal functioning, symptom adjustment, and caregiver burden, in addition to change measures, therapist variables and treatment adherence. At the secondary endpoints, 9 and 12 months after the beginning of therapy, we will again assess all outcomes. The study is expected to pilot test a RCT which will be the first to directly compare CBT and multi-person ST, integrating a broad range of systemic methods, for social anxiety disorders, and it will provide empirical evidence for the calculation of the number of patients needed for a confirmatory RCT. ClinicalTrials.gov: NCT02360033 ; date of registration: 21 January 2015.


  • Open Access

    Influx of multidrug-resistant organisms by country-to-country transfer of patients

    by Nico T. Mutters, Frank Günther, Anja Sander, Alexander Mischnik, Uwe Frank

    Multidrug-resistant organisms (MDRO) are a worldwide problem. International migration and travel facilitate the spread of MDRO. Therefore the goal of our study was to assess the risk of influx of MDRO from patients transferred to one of Central Europe’s largest hospitals from abroad. A mono-centre study was conducted. All patients transferred from other countries were screened; additional data was collected on comorbidities, etc. Presence of carbapenemases of multidrug-resistant Gram-negatives was confirmed by PCR. The association between length of stay, being colonized and/or infected by a MDRO, country of origin, diagnosis and other factors was assessed by binomial regression analyses. From 2012 to 2013, one fifth of all patients were colonized with MDRO (Methicillin-resistant Staphylococcus aureus [4.1 %], Vancomycin-resistant Enterococci [2.9 %], multidrug-resistant Gram-negatives [12.8 %] and extensively drug-resistant Gram-negatives [3.4 %]). The Gram-negatives carried a variety of carbapenemases including OXA, VIM, KPC and NDM. The length of stay was significantly prolonged by 77.2 % in patients colonized with a MDRO, compared to those not colonized (p<0.0001). Country-to-Country transfer of patients to European hospitals represents a high risk of introduction of MDRO and infection control specialists should endorse containment and screening measures.